French Stock News

Altareit’s share price has barely moved over the past week, yet the latest half year numbers confront investors with the same uncomfortable question. How much patience is left for a stock that still trades on a low 0.5x price to sales multiple while posting another loss in the tens of millions of euro. The headline this time is not revenue. It is the strain from continued losses and weak debt coverage sitting on a highly discounted valuation. Today’s flat reaction looks more like a pause...

Legrand walked into this earnings day with a tired chart and a rich story. The stock closed at €130.3, with the past month down about 11% and the last quarter down about 14%. Yet the latest numbers tell a different tale. Second quarter revenue reached €2,862.7m and basic earnings per share came in at €1.39. The real headline is that the margin engine is still working. Net profit over the last twelve months stands at €1.31b on €10.11b of revenue, keeping profitability close to recent levels...

Euroapi stock has been sliding for weeks, down about 27% over the past month and sitting under €1 before these H1 numbers hit the tape. Today's figures add a fresh twist. Revenue fell to €356.5m and the company booked a net loss of €141.5m, just as net debt swung to €37.9m from a net cash position at the end of 2025. That is the tension traders are wrestling with. The price hints at deep pessimism already baked in. The earnings headline is a sharp profit squeeze and a fast weakening balance...

Elis came into these half year numbers with a stock that has been grinding lower, down almost 9% over the past month and about 6% over three months, despite trading on a modest 14x trailing P/E. The headline from H1 2026 is steadiness rather than shock. Revenue reached €2,457.1m with organic growth of 3.2%, adjusted EBIT margin held at 15.1% and diluted headline EPS printed at €0.89. For a highly capital intensive textile, hygiene and facility services group, the lack of margin slippage is...

Tikehau Capital went into these earnings with a stock that has been quietly grinding lower, down about 9% over the past week and 11% over three months. That sets up a classic sentiment clash. The headline from H1 2026 is not about top line noise. It is about profitability in asset management, with core fee related earnings and margins in that business stepping into what management calls a harvesting phase. For a market focused on whether Tikehau Capital can turn growing assets into dependable...

Vicat shares closed at €67.20 after the half year 2026 release, with the stock already sitting on a 12% gain over the past three months. The headline is not the price move; the focus is a valuation gap that still looks wide for a cement producer generating €4,005.737m in trailing twelve month revenue and earnings per share of €6.51. In the short term, traders may debate a single half year margin print. In the longer term, investors are looking at a stock on a P/E of 10.3 that screens below...

L’Oréal came into this earnings print priced for perfection, trading at a P/E near 33x and only modestly below one discounted cash flow fair value estimate, while sitting on a solid run with a roughly 7% gain over the past 90 days. The market had already priced in quality. The headline today is that L’Oréal delivered on that reputation with record H1 operating margin of 21.3% and e commerce sales of €7.4b, supported by €3.1b in operating net cash flow. The question now is how much of that...

Icade reported half-year 2026 results showing sales of €170.2 million and revenue of €680.8 million, both lower than a year earlier, with net loss widening to €155.9 million and loss per share from continuing operations rising to €2.06. Alongside these weaker results, Icade’s Board approved the half-year accounts and appointed Raphael Appert as Chairman for a four-year term, signaling governance continuity amid operational pressures. We’ll now examine how the widening half-year net loss...

Hermès International Société en commandite par actions has seen its share price fall 32.9% over the past year, yet the valuation checks still suggest the stock is not a clear bargain. Over the last 12 months the stock is down 32.9%, which means recent buyers have faced a sharp reset in expectations. Stronger sales in leather goods and solid profitability can support the current market price, but softer areas such as perfume and beauty and regional pressures may weigh on how much investors...

Global inflation, energy prices and geopolitics are keeping markets on edge, yet they also keep attention on sectors tied to long-term government spending such as aerospace and defense. With central banks juggling growth and inflation, and consumer confidence improving in some regions but not others, many investors are looking for companies whose demand is shaped more by policy priorities than by short term swings in sentiment. The Aerospace And Defense screener helps you filter this space...

EssilorLuxottica Société anonyme walked into this earnings season with a premium P/E and a reputation as a quality compounder. Yet the stock closed at about €165.1 on 29 July, and is down roughly 9% over the past 90 days. The gap between that softer share price and the latest numbers is now front and center. The headline is margin quality. H1 2026 delivered adjusted operating profit growth faster than revenue, a higher gross margin and the strongest first half free cash flow in five years at...

Nexans (ENXTPA:NEX) is in focus after reporting half year 2026 earnings. Sales were €4,736 million, while net income was €103 million, with diluted EPS from continuing operations at €2.68. See our latest analysis for Nexans. Nexans shares trade at €128.6 after a 3.63% 1 day share price gain. However, the 30 day share price return is down 9.75% and the 90 day share price return is down 18.66%. The 5 year total shareholder return of 77.29% points to momentum that has built over a longer period...

Why the amlitelimab decision matters for Sanofi shareholders Sanofi (ENXTPA:SAN) is halting development of amlitelimab for moderate to severe atopic dermatitis after a pipeline review concluded the efficacy and safety profile did not justify regulatory submissions compared with current treatments. The company cited long term phase 3 data showing maintained clinical response and an emerging safety profile, yet still judged amlitelimab would not offer a meaningful improvement over existing...

Sopra Steria Group (ENXTPA:SOP) is back in focus after its board approved first half 2026 financial statements and raised the full year organic revenue growth target, supported by new contracts and acquisitions. See our latest analysis for Sopra Steria Group. The strong first half update appears to have acted as a clear catalyst, with Sopra Steria Group’s 1 day share price return of 13.59% feeding into a 90 day share price return of 47.62%. Meanwhile, the 5 year total shareholder return of...

After a strong five year run, with BNP Paribas returning 193.5%, the stock now trades close to where the intrinsic value estimate from the Excess Returns model and traditional earnings multiples both suggest it looks about right rather than obviously cheap. The 193.5% five year return puts BNP Paribas firmly in the camp of large banks that have already delivered substantial gains, which can limit the margin of safety at today’s price. Recent profit growth and expansion in markets like...

The half-year results for Compagnie Générale des Établissements Michelin Société en commandite par actions ( EPA:ML...

The interim results for LVMH Moët Hennessy - Louis Vuitton, Société Européenne ( EPA:MC ) were released last week...

PAULIC Meunerie SA ( EPA:ALPAU ), might not be a large cap stock, but it received a lot of attention from a substantial...

Shareholders might have noticed that Rexel S.A. ( EPA:RXL ) filed its half-year result this time last week. The early...

SMCP S.A. ( EPA:SMCP ), is not the largest company out there, but it received a lot of attention from a substantial...

Soft earnings didn't appear to concern SEB SA's ( EPA:SK ) shareholders over the last week. We think that the softer...

Bureau Veritas reported past-half-year 2026 sales of €3,361.2 million, modestly above last year, while net income and earnings per share from continuing operations declined versus the prior period. Alongside these results, the company reshaped its leadership team to drive its LEAP | 28 plan, adding new executive roles focused on corporate development, commercial performance, and operational excellence. We’ll now explore how the refreshed executive team and LEAP | 28 execution could influence...

Slovenia’s rise as a premium cycling hotspot, helped by stars like Tour de France champion Tadej Pogačar, is doing more than filling bike lanes. It is drawing higher spending visitors, new tour concepts, and fresh investment interest across travel and leisure. For investors who track how real world trends feed into listed companies, this is a theme worth watching. This article looks at how that cycling tourism story links back to the stock market and highlights three stocks from a travel and...

Why Rémy Cointreau Stock Is Back on Investors’ Radar Rémy Cointreau (ENXTPA:RCO) is in focus after first quarter sales reached €223.2 million compared with €220.8 million a year earlier, and the company reaffirmed its 2026-27 earnings margin guidance. See our latest analysis for Rémy Cointreau. Rémy Cointreau’s latest trading update comes as the stock has shown strong short term momentum, with a 30 day share price return of 14.11% and a year to date share price return of 35.04%, even though...